Advanced influenza vaccines: Led by science.

CSL Seqirus has been at the forefront of the scientific advancement in vaccine technology for over 100 years.

Science and innovation lie at the heart of everything we do

Influenza remains one of New Zealand's deadliest vaccine-preventable diseases,¹ making flu vaccines a top priority for research, development and production leading to innovative products such as:

An innovative cell-based flu vaccine designed to be an exact match to the circulating strains^2-5

Click here to find out more about Flucelvax Quad

FLUAD^® Quad was developed to offer enhanced protection against influenza for people 65 years of age or older, compared with the standard vaccine.⁶

Click here to find out more about FLUAD Quad

References: 1. Flu a major killer, InBrief, Otago Magazine, University of Otago, New Zealand. Available from: https://www.otago.ac.nz/otagomagazine/issue45/inbrief/otago664450.html. 2. Rajaram S et al. Ther Adv Vaccines Immunother.2020;8:2515135520908121. 3. CDC. Cell-based flu vaccines. Available from: www.cdc.gov/flu/prevent/cell-based.htm Accessed Dec 2024. 4. Mabrouk T et al. Dev Biol (Basel). 2002;110:125–134. 5. WHO. Influenza A(H3N2) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2022 SH influenza season; Available from: https://cdn.who.int/ media/docs/default-source/influenza/cvvs/cvv-southern-hemisphere-2022/A(H3N2)---cell-culture-derived.pdf-cell_sh21.pdf?ua=1 Accessed Dec 2024 6. CSL Seqirus. FLUAD® Quad Data Sheet. October 2023.

Flucelvax^® Quad is an unfunded Prescription Medicine. Flucelvax^® Quad is an inactivated quadrivalent influenza vaccine, prepared in cell cultures as a suspension for injection, in a single-dose glass syringe. PRESENTATION: Each dose contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains. INDICATIONS: For the prevention of influenza caused by Influenza Virus, types A and B, in adults and children 6 months of age and older. CONTRAINDICATIONS: Known severe allergic reaction (e.g. anaphylaxis) to a previous influenza vaccination or to any component of the vaccine. ADVERSE EVENTS: Local injection site pain, erythema and induration. Systemic headache, fatigue, myalgia, irritability, nausea, upper respiratory tract infection and nasopharyngitis. Post-marketing serious adverse events includes hypersensitivity reactions, anaphylactic shock; paraesthesia, Guillain-Barré syndrome; pruritus, urticaria, or non-specific rash; Extensive swelling of injected limb. PRECAUTIONS: Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients, particularly in immunosuppressed patients. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give Flucelvax® Quad should be based on careful consideration of the potential benefits and risks. Treatment and supervision for anaphylactic reactions should be available. Co-administration with other vaccines has not been studied. DOSAGE AND ADMINISTRATION: By intramuscular injection only. Gently shake to produce a clear to slightly opalescent suspension before use. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the Flucelvax^® Quad Data Sheet (June 2024) www.medsafe.govt.nz, Seqirus Auckland, 0800 502 757. Flucelvax^® Quad is a registered trademark of Seqirus UK Ltd or its affiliates.

FLUAD^® Quad is an unfunded Prescription Medicine. FLUAD^® Quad is an inactivated influenza vaccine, with an MF59^® Adjuvant, as a suspension for injection in a single-dose glass syringe. PRESENTATION: Each dose contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains INDICATIONS: For active immunisation against seasonal influenza for people 65 years of age and older. CONTRAINDICATIONS: Known severe allergic reactions to any component of the vaccine, except egg proteins; previous dose of any influenza vaccine. ADVERSE EVENTS: Common injection site pain, fatigue and headache. Most of these reactions disappear within 3 days. Rare but serious events include thrombocytopenia; lymphadenopathy; muscular weakness; allergic reactions such as anaphylactic shock, anaphylaxis; encephalomyelitis, Guillain Barré syndrome, neuritis, neuralgia, paraesthesia, convulsions; vasculitis with transient renal involvement; generalised skin reactions; and severe injection-site reactions (extensive limb swelling or cellulitis-like reactions). PRECAUTIONS: Postpone immunisation in patients with acute febrile illness or infection. Antibody responses may not be protective in all vaccinees, particularly in immunosuppressed patients. FLUAD® Quad is for intramuscular injection use only. Persons with a history of anaphylaxis to egg should be vaccinated only in medical facilities with staff experienced in recognising and treating anaphylaxis. Co-administration with other vaccines has not been studied. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, consider potential benefits and risks. DOSAGE AND ADMINISTRATION: Gently shake before use; inject a single 0.5 mL dose into the deltoid muscle. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the FLUAD^® Quad Data Sheet at www.medsafe.govt.nz, or from CSL Seqirus (NZ) Ltd, Auckland. FLUAD^® and FLUAD^® Quad are registered trademarks of Seqirus UK Ltd. 10/23 NZ-FLU-24-0006. TAPS DA 2414ER. Updated Dec 2024. INSIGHT 13360